PICAROS - スペインの 1L CLL に対するアカラブルチニブ RWE (PICAROS)
スペインにおけるアカラブルチニブの第一選択使用とその実際の転帰を説明する、慢性リンパ性白血病の未治療患者または第一世代BTKi不耐症患者を対象とした非介入コホート研究:PICAROS研究
This is a multicenter non-interventional study (NIS) of patients with CLL treated with first-line acalabrutinib according to routine clinical practice in Spain. It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).
調査の概要
状態
条件
詳細な説明
This is a multicenter, non-interventional study (NIS) based on ambispective (including retrospective and/or prospective) real-world data collection of patients with CLL who received treatment with acalabrutinib for the first time in Spain.
It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).
For the cohort 1, the start of acalabrutinib treatment (index date) was prior to the first site initiation visit. For both cohorts 1 and 2, the clinical decision of starting patient on acalabrutinib has to independently occur prior to the patient inclusion into this study. Patients' eligibility for study inclusion is regardless of their current status of acalabrutinib therapy, for example, patients already deceased or discontinued therapy are still eligible to be included into this study. Patient data will be collected both retrospectively and/or prospectively up to approximately 32 months from the first site initiation visit for cohort 1, and approximately 25 months after the inclusion of the last patient in the cohort 2. For patients who received acalabrutinib therapy and have deceased, only retrospective medical chart review will be conducted.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:AstraZeneca Clinical Study Information Center
- 電話番号:1-877-240-9479
- メール:information.center@astrazeneca.com
研究場所
-
-
Andalusia
-
Almería、Andalusia、スペイン、4009
- 募集
- Research Site
-
Córdoba、Andalusia、スペイン、14004
- 募集
- Research Site
-
Granada、Andalusia、スペイン、18014
- 募集
- Research Site
-
Jaén、Andalusia、スペイン、23007
- 積極的、募集していない
- Research Site
-
Marbella、Andalusia、スペイン、29603
- 積極的、募集していない
- Research Site
-
Málaga、Andalusia、スペイン、29010
- 積極的、募集していない
- Research Site
-
Seville、Andalusia、スペイン、41013
- 募集
- Research Site
-
-
Aragon
-
Zaragoza、Aragon、スペイン、50009
- 募集
- Research Site
-
Zaragoza、Aragon、スペイン、50009
- 積極的、募集していない
- Research Site
-
-
Balearic Islands
-
Palma de Mallorca、Balearic Islands、スペイン、7010
- 積極的、募集していない
- Research Site
-
Palma de Mallorca、Balearic Islands、スペイン、7198
- 積極的、募集していない
- Research Site
-
-
Basque Country
-
Donostia / San Sebastian、Basque Country、スペイン、20014
- 引きこもった
- Research Site
-
Galdakao、Basque Country、スペイン、48960
- 引きこもった
- Research Site
-
-
Canary Islands
-
Las Palmas de Gran Canaria、Canary Islands、スペイン、35016
- 積極的、募集していない
- Research Site
-
Las Palmas de Gran Canaria、Canary Islands、スペイン、35019
- 積極的、募集していない
- Research Site
-
San Cristóbal de La Laguna、Canary Islands、スペイン、38320
- 募集
- Research Site
-
-
Cantabria
-
Santander、Cantabria、スペイン、39008
- 積極的、募集していない
- Research Site
-
-
Castille and León
-
Salamanca、Castille and León、スペイン、37007
- 積極的、募集していない
- Research Site
-
Segovia、Castille and León、スペイン、40002
- 積極的、募集していない
- Research Site
-
Valladolid、Castille and León、スペイン、47003
- 積極的、募集していない
- Research Site
-
Valladolid、Castille and León、スペイン、47012
- 積極的、募集していない
- Research Site
-
-
Castille-La Mancha
-
Guadalajara、Castille-La Mancha、スペイン、19002
- 募集
- Research Site
-
Toledo、Castille-La Mancha、スペイン、45004
- 積極的、募集していない
- Research Site
-
-
Catalonia
-
Barcelona、Catalonia、スペイン、8003
- 積極的、募集していない
- Research Site
-
Barcelona、Catalonia、スペイン、8025
- 積極的、募集していない
- Research Site
-
Barcelona、Catalonia、スペイン、8035
- 積極的、募集していない
- Research Site
-
Barcelona、Catalonia、スペイン、8036
- 積極的、募集していない
- Research Site
-
Granollers、Catalonia、スペイン、8402
- 積極的、募集していない
- Research Site
-
L'Hospitalet de Llobregat、Catalonia、スペイン、8908
- 積極的、募集していない
- Research Site
-
Lleida、Catalonia、スペイン、25198
- 積極的、募集していない
- Research Site
-
Terrassa、Catalonia、スペイン、8221
- 積極的、募集していない
- Research Site
-
-
Galicia
-
Ourense、Galicia、スペイン、32005
- 募集
- Research Site
-
Santiago de Compostela、Galicia、スペイン、15706
- 積極的、募集していない
- Research Site
-
Vigo、Galicia、スペイン、36312
- 募集
- Research Site
-
-
Madrid
-
Madrid、Madrid、スペイン、28006
- 募集
- Research Site
-
Madrid、Madrid、スペイン、28031
- 積極的、募集していない
- Research Site
-
Madrid、Madrid、スペイン、28034
- 積極的、募集していない
- Research Site
-
Madrid、Madrid、スペイン、28905
- 積極的、募集していない
- Research Site
-
Madrid、Madrid、スペイン、28911
- 積極的、募集していない
- Research Site
-
Madrid、Madrid、スペイン、28040
- 募集
- Research Site
-
Madrid、Madrid、スペイン、28041
- 募集
- Research Site
-
Madrid、Madrid、スペイン、28046
- 募集
- Research Site
-
Majadahonda、Madrid、スペイン、28222
- 積極的、募集していない
- Research Site
-
-
Murcia
-
El Palmar、Murcia、スペイン、30120
- 積極的、募集していない
- Research Site
-
Murcia、Murcia、スペイン、30008
- 募集
- Research Site
-
-
Principality of Asturias
-
Oviedo、Principality of Asturias、スペイン、33011
- 積極的、募集していない
- Research Site
-
-
Valencia
-
Alicante、Valencia、スペイン、3010
- 募集
- Research Site
-
Valencia、Valencia、スペイン、46010
- 積極的、募集していない
- Research Site
-
Valencia、Valencia、スペイン、46014
- 積極的、募集していない
- Research Site
-
Valencia、Valencia、スペイン、46026
- 積極的、募集していない
- Research Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study aims to include approximately 315 patients in the cohort 1 and 103 patients in the cohort 2 who started acalabrutinib for the first time for the treatment of their CLL. To minimize selection biases, all patients (alive or deceased) identified on acalabrutinib will be eligible for inclusion into the study. These patients will be included from approximately 50 hospitals distributed throughout Spain.
説明
Inclusion Criteria:
- Age ≥18 years old at starting acalabrutinib treatment.
- Diagnosis of CLL.
- Start of acalabrutinib treatment (index date) as per the CLL SmPC:
- in treatment-naïve CLL patients or those switching in first-line between first-generation BTK inhibitor to acalabrutinib due to intolerance in absence of progression according to routine clinical practice within the year before the first site initiation visit (cohort 1).
- in treatment-naïve CLL patients for the fixed-duration treatment combination of acalabrutinib plus venetoclax (with or without obinutuzumab) according to routine clinical practice from the EMA approval (i.e., 2 June 2025) (cohort 2).
Decision to administer acalabrutinib must be made and documented prior to inclusion into the study and must follow local clinical practice.
- Informed consent (for alive patients).
Exclusion Criteria:
- Enrolled in any clinical trial during acalabrutinib treatment.
- Patients who are unable to understand the study and its questionnaires due to insufficient knowledge of the Spanish language or their health status.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:OTHER
コホートと介入
グループ/コホート |
|---|
|
Cohort 1
Patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit as per routine clinical practice, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression. |
|
Cohort 2
Patients with first-line fixed-duration acalabrutinib use with venetoclax in routine clinical practice. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).
時間枠:24 months after treatment initiation (cohort 1).
|
Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1). In addition to this outcome measured in the overall cohort, it will also be assessed by the following factors:
|
24 months after treatment initiation (cohort 1).
|
|
Real-world overall response rate (rwORR) achieved until the end of the observational period for first-line fixed duration acalabrutinib therapy (cohort 2)
時間枠:From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.
|
rwORR (i.e., the proportion of patients that achieved complete or partial response) achieved until the end of the observational period for first-line fixed-duration acalabrutinib therapy as assessed by the treating physician (cohort 2). Complete response may include complete response, complete response with incomplete marrow recovery, or unconfirmed complete response (marrow biopsy not performed). Partial response may include partial response, or partial response with lymphocytosis. The rwORR will be assessed by the treating physician in routine clinical practice, including the use or not of the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. The end of observational period for first-line fixed-duration combinations of acalabrutinib is defined as the start date of a subsequent line therapy or study end date, whichever comes first. |
From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Acalabrutinib±venetoclax doses (cohorts 1 and 2).
時間枠:At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
Acalabrutinib±venetoclax doses (e.g., starting does and dose adjustments), overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). In cohort 2, doses (e.g., starting dose, dose adjustments, maximum dose achieved) and reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the time to reach the maximal dose. |
At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
Patients with acalabrutinib±venetoclax dose adjustments (n, %), temporary interruptions (n, %), and permanent discontinuations (n, %) (cohorts 1 and 2).
時間枠:From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
Acalabrutinib±venetoclax dose adjustments, temporary interruptions, and permanent discontinuations, overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). In patients with regimen modifications within cohort 2, the proportion of patients with these regimen modifications and the time from treatment initiation to the regimen modification within same line therapy prior to progression (e.g., treatment duration and number of cycles prior to the modification, and reason for the modification). In cohort 2, temporary interruptions, permanent discontinuations, and their reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the proportion of patients requiring dose reductions after achieving maximum dose. |
From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
Treatment duration in months (cohorts 1 and 2).
時間枠:From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
Treatment duration (cohorts 1 and 2), overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). In cohort 2, also median number of completed cycles and the proportion of patients who complete 14 cycles. Baseline patient characteristics associated with treatment duration in multivariate analyses, overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). |
From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib (cohort 1).
時間枠:From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).
|
Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib, overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1). The PDC will be based on data available on acalabrutinib treatment in pharmacy records, and defined as the percentage of days a patient has the medication available in a given period of time: PDC (%)=(No.days covered)/(No.days of interest)×100 |
From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).
|
|
TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause) (cohorts 1 and 2).
時間枠:From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause [i.e. deaths are not censored]), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). |
From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause) (cohorts 1 and 2).
時間枠:From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). |
From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
|
Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation; that are considered serious during acalabrutinib±venetoclax treatment; and events of clinical interest (cohorts 1 and 2).
時間枠:From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation. Adverse events that are considered serious (including fatal events) during acalabrutinib±venetoclax treatment, globally and treatment related (when available). Events of clinical interest (atrial fibrillation, hypertension, bleeding, infections, ventricular arrhythmias, hepatotoxicity, secondary primary malignancies, cytopenia, and pneumonitis) during acalabrutinib treatment, globally and treatment related (when available). They will be described overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only). |
From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- D8221R00003
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD 共有時間枠
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共有アクセス基準
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。